Inflammatory Bowel Disease Research Program
The Inflammatory Bowel Disease Research Program at NYU Langone Health bridges basic, clinical, and educational disciplines and brings together faculty who build on the breadth of our immunology, microbiology, and cell biology research to foster cross-disciplinary collaborations and studies. Our mission is to build on our institution’s tradition of turning basic science discoveries into treatments for inflammatory bowel diseases (IBD) including Crohn’s disease and ulcerative colitis.
Following their research on immune signaling molecules, NYU Langone microbiologists worked with pharmaceutical companies to develop the drug infliximab, which blocks one such molecule called TNF-α. It remains among the most commonly used therapies for IBD.
Faculty at the Inflammatory Bowel Disease Research Program work hand-in-hand with gastroenterologists and surgeons at NYU Langone’s clinical Inflammatory Bowel Disease Center with the goal of discovering new treatment strategies and how best to apply them to improve patient care.
Ken H. Cadwell, PhD, the Recanati Family Professor of Microbiology and professor in the Departments of Microbiology and Medicine is our program director. Dr. Cadwell is recognized for his research on how our immune system is regulated by the diverse microbes we encounter throughout our lives. His discoveries have contributed to our understanding of how imbalances in our relationship with microbes in the gut can lead to inflammation, as seen in patients with IBD.
Dr. Cadwell works together with other members of the leadership team to integrate basic and clinical research with training objectives of the Inflammatory Bowel Disease Research Program. Jordan E. Axelrad, MD, MPH, directs our clinical and translational inflammatory bowel disease research efforts and oversees the gastrointestinal diseases biorepository. Dr. Axelrad is recognized for his research on malignant and infectious complications of IBD, specifically, in elucidating how exposures such as gastrointestinal infections may complicate IBD or trigger it to develop.
David P. Hudesman, MD, and Feza Remzi, MD, are co-directors of our Inflammatory Bowel Disease Center. Together with Dr. Cadwell and Dr. Axelrad, they manage IBD research studies and clinical trials representing partnerships among clinicians, scientists, and industry.
We are hiring research scientists to join our team. Learn more about our available positions.
Select Faculty Publications
Early Initiation of Antitumor Necrosis Factor Therapy Reduces Postoperative Recurrence of Crohn's Disease Following Ileocecal Resection
Inflammatory bowel diseases. 2023 Jun 01; 29:888-897
Development of the Endoscopic Pouch Score for Assessment of Inflammatory Conditions of the Pouch
Clinical gastroenterology & hepatology. 2023 Jun ; 21:1663-1666.e3
Health Status and Clinical Outcomes in Older Adults With Chronic Coronary Disease: The ISCHEMIA Trial
Journal of the American College of Cardiology. 2023 May 02; 81:1697-1709
Could Meeting the Standards of the National Accreditation Program for Rectal Cancer in the National Cancer Database Improve Patient Outcomes?
Colorectal disease. 2023 May ; 25:916-922
Platelet LGALS3BP Induces Myeloid Inflammation In Systemic Lupus Erythematosus
Arthritis & rheumatology. 2023 May ; 75:711-722
Immune-Epithelial Cross Talk in Regeneration and Repair
Annual review of immunology. 2023 Apr 26; 41:207-228
Expanding the use of brief cognitive assessments to detect suspected early-stage cognitive impairment in primary care
Alzheimer's & dementia. 2023 Apr 19;
Crosswalk between Charlson Comorbidity Index and the American Society of Anesthesiologists Physical Status Score for Geriatric Trauma Assessment
Healthcare (Basel). 2023 Apr 15; 11: